Dupixent vs Rinvoq
Dupilumab vs Upadacitinib · Comparison Guide
Quick Comparison
| Feature | Dupixent | Rinvoq |
|---|---|---|
| Generic Name | Dupilumab | Upadacitinib |
| Manufacturer | Sanofi/Regeneron | AbbVie |
| Drug Class | IL-4/IL-13 Inhibitor | JAK1 Inhibitor |
| Shared Conditions | Atopic Dermatitis | |
Key Differences: Dupixent vs Rinvoq
Both are approved for moderate-to-severe atopic dermatitis. Head-to-head trials (Heads Up, Jade Compare) showed Rinvoq achieved numerically higher EASI-75 and IGA scores at certain timepoints compared to Dupixent. However, Rinvoq carries a black box warning for serious infections, malignancies, and thrombosis. Dupixent has no required lab monitoring. Prescriber preference, patient age, and cardiovascular risk factors influence the choice.
💊 Dupixent (Dupilumab)
- Class: IL-4/IL-13 Inhibitor
- Manufacturer: Sanofi/Regeneron
- Full Dupixent information →
💊 Rinvoq (Upadacitinib)
- Class: JAK1 Inhibitor
- Manufacturer: AbbVie
- Full Rinvoq information →
Both are approved for moderate-to-severe atopic dermatitis. Head-to-head trials (Heads Up, Jade Compare) showed Rinvoq achieved numerically higher EASI-75 and IGA scores at certain timepoints compared to Dupixent. However, Rinvoq carries a black box warning for serious infections, malignancies, and thrombosis. Dupixent has no required lab monitoring. Prescriber preference, patient age, and cardiovascular risk factors influence the choice.
Neither Dupixent nor Rinvoq is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Dupixent and Rinvoq are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Dupixent and Rinvoq both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Dupixent and Rinvoq
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Dupixent and Rinvoq should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.